Federal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
A US federal court has ruled that four patents relating to Allergan’s Restasis (ciclosporin) eye drops are invalid. The ruling opens the way for challengers Mylan and Teva to introduce generic versions. Allergan has said it will appeal the decision.